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ABSTRACT
Hydroquinone is used extensively as a photographic developer. The
metabolic fate and percutaneous absorption of [U-^4C]HQ was determined
in male Beagle dogs. The excretion of 14C was determined after dermal
exposure, intravenous (iv) and gavage administrations. For iv studies,
1 or 10 mg/kg of [14C]HQ was injected and blood, urine and breath were
collected for 8-12 hours in anesthetized dogs. After recovery from the
anesthetic, dogs were housed in metabolism cages for 6 to 7 days for
collection of blood, urine and feces. Blood **C concentrations
declined slowly, with 2 apparent phases. Half-life values for the a
and 3 phases were 1.3 and 7.2 hours for the 1 mg/kg dose and 1.0 and
8.0 hours for the 10 mg/kg dose, respectively. Excretion of 14C was
rapid initially, with 14.6% and 42.4% of the ^C being excreted in 4
hours for the 1 and 10 mg/kg doses, respectively. Values for urine,
feces and total recovery of ^4C at 4 to 7 days were 34.5%, 7.1%, and
41.6% for a 1 mg/kg dose and 65.7%, 6.1%, and 71.8% for a 10 mg/kg dose.
No **C was detected in the expired air. The concentration of **C in
the skin 24 hours after iv dosing of 1 mg/kg [14C]HQ was about 10.4%
of the dose. The other tissues showed low concentrations of ^4C.
After the oral administration of 50 mg/kg [^^C]HQ to dogs, blood **C
concentrations declined slowly. Half-life values for the a and B
phases were 0.85 and 12.5 hr, respectively. The urinary excretion
pattern was similar to that seen after iv administration, with 62.5% of
the dose being excreted after 4 hours. Values for urine, feces, blood,
tissue, and total recovery of ^*C at 5 to 7 days were 80.4%, 3.7%,
0.15%, 2.2%, and 86.5%. Analysis for urinary metabolites indicated that
the urine of iv and orally-treated dogs did not contain sulfates or
glucuronides of HQ as was reported elsewhere for rats dosed orally with
[14C]HQ. After dermal application of [14C]HQ, no 14C was detected
in the blood. Urinary excretion of 14C accounted for only 0.03% of
the applied radioactivity at 2 days and 0.04% at 5 days. Urinary 14C
was still detectable at 5 days. The percutaneous absorption rate was
about 0.16 nmol/cnr/min (1.1 ug/cm2/hr). Using these data to
estimate human uptake, assuming immersion of both hands into a
photographic developer solution containing HQ for 1 hour, about 0.8 mg
of HQ would be absorbed through the skin.
These studies compare the metabolic fate of HQ by different routes
of administration and show that HQ is poorly absorbed through the skin.
INTRODUCTION
Hydroquinone (1,4-dihydroxybenzene) , is a six carbon aromatic
compound with phenolic hydroxyl groups in the para-position. It is a
white crystalline solid at room temperature and is soluble in water,
ethanol, acetone, ether and chloroform.
Hydroquinone is an effective antioxidant for non-food industrial
fats and oils and is used as an intermediate in the production of dyes
and in the manufacture of other antioxidants such as butylated
hydroxyanisole (BHA) and monotertiary butyl hydroquinone (TBHQ)
(Mathtech, 1983). Because of its oxidation potential, hydroquinone is
widely used in industry as a developing agent for black and white
photographic film. Hydroquinone chemically reduces silver nitrate in
a photographic emulsion to metallic silver, and forms colored reaction
products with strong alkali and with concentrated sulfuric acid
(Mansville Chem. Prod., 1978). Hydroquinone is also used in
dermatologic products as a bleach for hyperpigmented skin and has also
been used to prevent oxidative degradation of vitamin A in medicinal
and biological preparations (Raff and Ettling, 1966).
Hydroquinone and quinone are chemically interconvertible and form
a reversible redox system. In the dry, crystalline form, pure
hydroquinone is quite stable, and darkens slowly upon prolonged
exposure to air. In the presence of moisture (at temperatures not
exceeding 37C) it readily undergoes oxidation via an intermediate
semiquinone radical to form quinone (Carmichael and Mander, 1967). In
aqueous solution, hydroquinone reacts with oxygen and undergoes autox-
idation. The initial products are quinone and hydrogen peroxide (Raff
and Ettling, 1966).
Regarding its environmental effects, quinone and hydroquinone are
known to be toxic to unicellular and multicellular aquatic plants.
Toxicity to aquatic plants has been reported to include inhibition of
respiration, abnormalities in photosynthesis and mortality. The effects
of hydroquinone and quinone on terrestrial higher plants include chromo
some aberrations, inhibition of growth, interference with seed
germination and inhibition of enzyme activity (Dynamac Corp. 1982).
Both quinone and hydroquinone are toxic to fish. Hydroquinone altered
tyrosinase activity in skin homogenates of the black gold fish,
Carassius auratus (Chen and Chavin, 1976).
Oral or parenteral administration of large doses of hydroquinone
to mammals rapidly produced nausea, salivation, tremors of the voluntary
muscles, convulsions and finally death by respiratory failure (Woodard,
1951). In dogs and cats given large sublethal doses (100 mg/kg of body
weight) , swelling of the mucous membrane of the lips and eyes was observed
within a few hours and lasted for 24-72 hours. Rats dosed with up to 1%
hydroquinone in the diet were without apparent toxic effects. However,
adult rats given 5% hydroquinone in the diet for 9 weeks showed significant
weight loss and developed aplastic anemia (Carlson and Brewer, 1953).
Repeated topical application of (1 and 3%) hydroquinone caused a
localized depigmentation of mammalian skin and hair. Denton et al. ,
(1952) reported depigmentation in adult black male mice given
hydroquinone by subcutaneous injection.
Several investigators have studied the metabolism of hydroquinone
in humans and experimental animals. Hydroquinone, administered by
gavage to 50 male rats at doses of 7.5 and 15 mg/kg, 6 days/week for 40
days had no effect on the weight gain, but hematological effects such as
anisocytosis, polychromatophilia and erythroblastosis were observed
(Delcambre et al. , 1962).
Studies by Garton and Williams (1949) showed that hydroquinone was
readily absorbed from the gastrointestinal tract in the rat and was
eliminated in the urine as conjugates with sulfuric or glucuronic acid.
In the rabbit, 43% of an administered oral dose was excreted in the
urine as the monoglucuronide and 30% as the sulfate ester.
DiVincenzo et al. , (1984), found that rats given a single dose of
14
200 mg/kg of [ C]hydroquinone orally, excreted 91.9% of the dose in
the urine within 2-4 days. The feces contained 3.8% of the dose and
about 0.4% was excreted in the expired air. Radioactivity was widely
distributed throughout the tissues with the highest concentrations found
in the liver and kidneys. About 25-42% of the dose was excreted as hydro
quinone monosulfate and 56-66% of the dose as hydroquinone monoglucuronide.
Estimates of absorption of oral doses of hydroquinone in man, dog
and rabbit based on urinary excretion data were considerably lower
than dose values reported for the rat (Dynamac Corp., 1982).
In view of the limited information concerning the dermal exposure
of hydroquinone and because of the potential for dermal contact with
photographic processing solutions, the percutaneous absorption of
14
[ C]hydroquinone and its disposition and metabolic fate following
an oral and intravenous administration was investigated in dogs . This
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[U- C]Hydroquinone was purchased from Wizard Laboratories
(Davis, CA) with a specific radioactivity of 5.0 mCi/mmol. Its
radiochemical purity was greater than 99% as determined by high
14
performance liquid chromatography (hplc).
[U- C]Hydroquinone was
dissolved in degassed, distilled water and diluted to a concentration
of 100 uCi/mL, placed in amber vials and stored at approximately
- 20C. Unlabeled hydroquinone was obtained from Eastman Kodak Co.,
Rochester, NY. No impurities were detected by gas chromatography/mass
spectrometry (GC/MS).
Animals
Male Beagle dogs weighing 9-15 kg, were purchased from Marshall
Research Animals, Inc. (North Rose, NY). They were identified by
ear tattoo. Dogs were held in quarantine for at least one week
prior to use. Prior to dosing, dogs were fasted for 16 hours and
water was provided ad libitum.
Methods
Intravenous Administration
Radiolabeled hydroquinone was dissolved in a degassed saline
solution containing unlabeled hydroquinone and about 3 or 4 mL of the
solution was administered through an indwelling foreleg intravenous
catheter at dose levels of 1 mg/kg (10 or 100 uCi) and 10 mg/kg of
body weight (30 uCi). A total of eight dogs was studied at the
lower dose, and three dogs at the high dose.
Expired air was collected continuously for 8 hours (from two sets
of dogs, at the lower dose) into a polytetrafluoroethylene bag by
means of an oral endotracheal tube connected to a two-way valve. The
contents of the bag were pumped through a silica gel trap to collect
volatile organic materials and through a sodium hydroxide trap (200 mL
of 2.5N sodium hydroxide) to collect respiratory carbon dioxide.
Traps were changed at 4 and 8 hours. Urine samples were collected at
4, 8 and 12 hours by means of a urethral catheter and blood samples
were collected periodically for the first 8 or 12 hours by means of an
indwelling forelimb catheter. A continuous saline drip was maintained
throughout each experiment to replace lost body fluids. After
recovery from the anesthetic, urine, feces and blood samples were
collected daily for up to 6 or 7 days from conscious dogs housed in
metabolism cages. Samples were either analyzed immediately after
collection or preserved with ascorbic acid and stored frozen until
analysis.
Major organs and tissues were excised from two dogs at time of
sacrifice and assayed for residual radioactivity.
Administration by Gavage
The disposition and excretion of hydroquinone was studied in
14
dogs after oral gavage administration of [ C]hydroquinone. Each
dog was strapped separately in a large sling (Harvard Apparatus Co.,
Inc., South Matick, MA), designed to restrain the animal in an
upright position with a minimum of fatigue. The sling was equipped
with zippers to give access to the front or the rear of the animal,
and to facilitate the removal of the catheters. Ace-Promazine
was administered as a tranquilizer. Approximately 125 uCi of
14
[ C]hydroquinone was dissolved in 25 mL of degassed water
containing unlabeled hydroquinone. Twenty milliliters of this
preparation (50 mg/Kg, 100 uCi) was given by gastric intubation to
each dog, followed by 20 mL of water. The dog remained in the sling
for about 8 hours, during which time the total volume of urine was
collected by means of a urethral catheter, and blood samples
collected in heparinized tubes at various intervals from an
indwelling forelimb catheter. Subsequently, urine and blood samples
were collected from dogs housed in metabolism cages for up to 7
days. Feces were collected up to 6 days. The dog was sacrificed
and all major organs and tissues were removed for the determination
of residual radioactivity. A total of two dogs was studied.
Skin Exposures
A suitable area of skin on the dog's thorax was shaved 24 hours
prior to a skin absorption study. Atropine sulfate and
Ace-Promazine were administered as pre-anesthetics . Dogs were
anesthetized with sodium pentobarbital for an initial collection
period of 8 or 12 hours.
14
[ C]Hydroquinone was added to 25 mL of a saline solution
containing unlabeled hydroquinone, to give a final hydroquinone
concentration of approximately 4.5 g/L (a concentration equivalent
to that found in commercial
"black-and-white"
developers). A
portion of this solution (approx. 40 yCi, 15 mL) was added to a
sealed glass absorption cell which was secured to the dog's thorax
with surgical adhesive (Skin Bond. Howmedica, Inc., Largo, FL)
and tape. The absorption cell adapted from the design of Wiirster
and Munies (1965) was 15 cm long, 3 cm wide at one end, 4 cm wide at
the other end and 1.5 cm deep. Cotton gauze was placed inside the
cell to facilitate the uniform distribution of the solution over the
surface of the skin. The surface area of the skin exposed to
2
hydroquinone was 55.6 cm . Exposures were carried out for 60
minutes, after which the skin was washed thoroughly with soap and
water. Blood samples and urine were collected at intervals up to
48 hours and 120 hours respectively, and were analyzed for
radioactivity. A total of six dogs was studied.
The skin absorption rates were calculated as nanomoles (nmoles)
14 2
of [ C]hydroquinone absorbed through the skin per cm of skin
surface area per unit of time. The method was based on the
procedure known as excretion analysis. The urinary excretion of
radioactivity after skin exposure and intravenous administration was
measured. The dermal absorption rate was then calculated after
correction for incomplete excretion of radioactivity using the data
obtained from intravenous experiments.
Radioactivity Measurements
All radioactivity measurements were carried out either with a
Packard Model 2660 Tri-Carb (Packard Instrument Co., Downers Grove,
IL) or with a LKB Model 1217 Rack Beta (LKB Instruments, Inc.,
Gaithersburg, MD) liquid scintillation spectrometer- Efficiency
corrections were made by external standardization. Radioactive
samples were dissolved in Eastman Ready-to-Use II scintillation
fluid (Eastman Kodak Company, Rochester, NY). Sodium hydroxide trap
solutions were counted directly in a scintillation fluid composed of
500 mL p-dioxane, 60 g naphthalene, 2.0 g PPO, 0.25 g P0P0P and
22.5 g Cab-0 Sil . Blood, feces and tissues were combusted
using a Packard Sample Oxidizer (Model 306), and counted in a
scintillation fluid containing Permaflour and Carbosorb .
10
Determination of Radioactivity in Excreta. Blood and Tissues
Urine was counted directly in scintillation fluid. Fecal
samples were homogenized with water, and transferred to flasks that
were manually rotated in a freezing bath containing acetone and dry
ice. Samples were then lyophilized using a Virtis, Freezemobile II
(Model 10-145V) . The dried residues were combusted directly.
Blood samples were combusted directly. All tissues except bone,
fat and skin, were homogenized with water, using a homogenizer or a
blender. Portions of this homogenate were combusted directly. Fat
and representative areas of skin were combusted directly. Cleaned,
chopped femoral bone was placed in a flask with an equivalent volume
of 70% perchloric acid and heated in a water bath at 60-70C
overnight, until solubilization was complete. Digested samples were
then combusted directly.
Characterization of Metabolites in Urine
Processing of Urine
All urine from the iv administration and from the gavage dosing
were thawed and filtered by passage through a 0.45 \tm Millipore
filter. Untreated whole urine from four-hour collections was
analyzed directly by hplc. The hplc radioactive peaks were
collected according to retention time. Fractions collected from 24
11
analyses of whole urine were pooled. Total radioactivity in each
fraction was determined by liquid scintillation counting (200 uL) .
Subsequently the pooled fractions were evaporated to dryness using a
Biichi Rotovapor (Model R110) at 40C. The residue was dissolved in
3.0 mL of methanol, assayed for radioactivity and re-analyzed by
hplc. A control urine was treated similarly. Samples were also
submitted for analysis by gas chromatography/mass spectrometry.
Urine was also extracted prior to hplc analysis. Four-hour urine
collections from three dogs (10 mg/kg dose) were pooled. Prior to
analysis, duplicate 1.0 mL aliquots of urine, adjusted each to 3.0 mL
with distilled water, were passed through two separate Bond Elut
C18 cartridges (Analytichem International, Inc., Harbor City, CA) .
The cartridge was previously activated by rinsing first with 5.0 mL of
methanol followed by 5.0 mL of water. Urine was washed from the
column with triplicate 1.0 mL portions of 20% methanol/80% formic acid
(0.09%). Radioactivity was quantitatively removed by this procedure.
The pooled extract was evaporated under reduced pressure at 40C to
approximately 1.0 mL, assayed for radioactivity and analyzed by hplc.
A control urine was treated similarly. Radioactive peaks detected on
hplc analysis of unhydrolyzed urine extracts were collected according
to retention time. The fractions were evaporated under reduced
pressure at 40C and the residue dissolved in 2.0 mL of methanol.
Samples (100 uL) were reanalyzed by hplc and submitted for analysis
by gas chromatography /mass spectrometry.
12
Portions of the untreated whole urine or urine extracts were
treated with P-glucuronidase to hydrolyze conjugates. Urine
extracts (0.5 mL) was diluted to 1.5 mL with distilled water. A
portion of this extract (0.5 mL) was placed in an amber vial and was
treated with 0.125 mL of a working solution of P-glucuronidase
(from bovine liver, approximately 5000 Fishman units /mL, type B-10,
Sigma Chemical Co., St. Louis, MO), prepared in a sodium acetate
buffer (0.1 - 0.5M), pH 5.5. The capped vial was incubated at 37C
in a water bath (4-24 hours).
Portions of urine or urine extracts were incubated with
sulfatase to hydrolyze the sulfate conjugates. Five tenths (0.5) mL
of sample (whole urine or extracted urine) were incubated with aryl
sulfatase/B-glucuronidase (1800 Fishman units /mL, Calbiochem, La
Jolla, CA or Sigma Chemical Co., St. Louis, MO). Saccharolactone
(10-50 mM) in sodium acetate buffer was added to inhibit the
activity of the P-glucuronidase. The samples were incubated as
above .
Urine from oral and iv dosing were also treated with
hydrochloric acid to hydrolyze sulfuric acid esters. A portion of
14
the C urine (0.5 mL) was treated with an equal volume of 3N HCl
in a 3.5 mL amber vial, heated in boiling water for 1 hour, cooled





A hplc reverse phase method was used to analyze the [ C]
hydroquinone and the urine samples. The method was adapted from
Greenlee et al. , (1981). A Waters high performance liquid
chromatograph equipped with a WISP 710 injection system, a 720
System Controller and Data Module was used (Waters Associates,
Milford, MA). A Spectroflow absorbence detector (Model 773) at
295 nm was used (Kratos, Westwood NJ) . The radioactivity in the
14
column eluate was detected with a C Berthold LB 504 detector,
fitted with a 400 uL glass cell. The eluant from the column was
collected using a SuperRac fraction collector, Model 2211 (LKB,
Washington, DC). Columns used were two 10 cm x 4.6 mm Spheri-10
RP-18 MPLC cartridges, with a 3 cm guard column (Browlee Labs,
Santa Clara, CA) . The mobile phase was methanol/0.09% formic acid
with the following gradient.
Time Flow (mL/min) % Formic Acid % Methanol
Initial 0.7 100 0
20.0 0.7 10 90
25.0 0.7 10 90
30.0 1.5 100 0
35.0 0.7 100 0




The recovery of radioactivity from male Beagle dogs dosed with
14
[ C]HQ is presented in Table 1. After iv administration of
14 14
1 mg/kg or 10 mg/kg [ C]HQ, urinary excretion of C was rapid
initially (Figure 1). The 8 hour and 24 hour cumulative excretion
totals were 20% and 26% for the 1 mg/kg dose and 53% and 60% for the
10 mg/kg dose. The majority of the urinary radioactivity (14.6% and
42.4% of the dose for 1 mg/kg and 10 mg/kg, respectively) was
eliminated within the first 4 hours. For each dose level, only an
additional 6 to 7% of the dose was excreted from day 2 to day 5. At
7 days after a 1 mg/kg dose, about 34.5% of the dose was accounted
for in the urine. Total urine radioactivity for a 10 mg/kg dose was
65 . 7% of the dose at 5 days . Fecal radioactivity accounted for
about 4.6% and 2.5% of the dose at 48 hours for the 1 mg/kg and
10 mg/kg doses, respectively. Total fecal radioactivity was 7.1%
and 6.1% for 1 mg/kg and 10 mg/kg, respectively by 4 to 5 days.
Elimination of radioactivity in the expired air after a 1 mg/kg dose
was below the limit of detection (less than 0.05% of the dose).
The overall recovery of radioactivity at 4 to 7 days was 41.6%
and 71.8% for 1 mg/kg dose and 10 mg/kg dose, respectively. Blood
radioactivity comprised
between 7 to 8% of the administered dose at
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Figure 1. The cumulative urinary excretion of radioactivity by dogs
after a single intravenous administration of [U-14C]hydroquinone
(1 mg/kg, D; 10 mg/kg, A). Values represent the mean from 3 to 8
dogs with standard errors shown as vertical bars , except where only
two values were determined. Urine was treated with ascorbate and was
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The blood concentration of radioactivity, expressed as nmole
14
equiv./mL after iv administration of [ C]HQ is shown in Figures 2
and 3. After iv administration of 1 mg/kg or 10 mg/kg, blood C
concentration declined slowly from 19.0 nmole equiv./mL at 5 minutes
to 1.1 nmole equiv./mL by 24 hours for 1 mg/kg; and from 133.2 nmole
equiv./mL at 5 minutes to 11.4 nmole equiv./mL by 24 hours for
10 mg/kg. Elimination kinetics for the first 24 hours revealed
evidence of an apparent absorption and elimination phases. The
estimated half life values for the 1 mg/kg studies were 1.3 and
7.2 hr for the a and P phases, respectively (Figure 2). For the
10 mg/kg studies, half-life values for the a and P phases were
1.0 and 8.0 hr, respectively (Figure 3).
Concentrations of radioactivity in excised tissues 24 hours
14
after iv dosing with [ C]HQ (1 mg/kg) are presented in Table 2.
14
The highest concentration of C was detected in the skin and was
equivalent to about 10.4% of the dose. The liver and the intestines
contained about 0.6% and 0.5% of the dose, respectively. The other
14
tissues examined showed low concentrations of C.
20
Figure 2. Concentration of radioactivity in the blood following
intravenous administration of [U-14C]hydroquinone (1 mg/kg) to male
Beagle dogs. Blood samples (0.3 mL) were combusted directly, using a
Packard Sample Oxidizer and counted in a scintillation fluid
containing Permaflour and Carbosorb. 14C disintegrations per
minute (dpm) was converted to nmol equivalents hydroquinone/mL
blood. Calculated half-life values (hr) : a = 1.3, P = 7.2.
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Figure 3 . Concentration of radioactivity in the blood following
intravenous administration of [U-^-4C]hydroquinone (10 mg/kg) to
male Beagle dogs. Blood samples (0.3 mL) were combusted directly,
using a Packard Sample Oxidizer and counted in a scintillation fluid
containing
Permaflour and Carbosorb. -^C disintegrations per
minute (dpm) was converted to nmol equivalents hydroquinone /mL
blood. Calculated half-life values (hr) : a = 1.0, P = 8.0.
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TABLE 2
Tissue Distribution of Radioactivity in Dogs Dosed Intravenously
with 1 mg/kg of [U-14C]Hydroquinone
(a)














































Dogs were sacrificed at 24 hours.
Values are expressed as average for two dogs.
Assuming 0.61
m2 for 11.5 kg. dog. Surface area calculated
using the formula: Area (sq. cm.)
= 11.6 x weight 2/3-
25
Table 3 shows the percentage of the administered dose recovered
in the urine, feces, blood and tissues after an oral administration
14
of 50 mg/kg [ C]HQ. About 63% of the dose was excreted in the
urine by 4 hours. The excretion pattern was similar to that seen
after iv administration (Figure 4). After an initial rapid
excretion, radioactivity declined slowly. The 24 hour cumulative
14
excretion of C was 78.1% of the dose, and an additional 2% of
the dose was excreted during the following 4 days. At 7 days about
80.4% of the dose was accounted for in the urine. The total
excretion of radioactivity in the feces was 2.3% and 3.2% of the
dose at 24 and 48 hours, respectively. Only an additional 0.6% of
the dose was eliminated by 5 days. The concentration of
radioactivity in the blood accounted for 2.5% of the dose at 4 hours
and declined to about 0.15% by 7 days. Tissue distribution of
14
radioactivity 7 days after oral administration with [ C]HQ is
shown in Table 4 . The concentration of radioactivity in the tissues
other than skin was low. The liver contained 0.3% of the dose.
Values for other tissues were less than 0.1% of the dose. The skin
contained approximately 1.8% of the dose.
The blood concentration of radioactivity after oral
14
administration of [ C]HQ expressed as nmole equiv./mL is shown in
14
Figure 5. The blood concentration of C declined from 309 nmole



























































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4. The cumulative urinary excretion of radioactivity by dogs
after a single dose by gavage with [U-14C]hydroquinone (50 mg/kg).
Values represent the mean from 2 dogs. Urine was treated with
ascorbate and was subsequently counted directly in scintillation
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TABLE 4
Tissue Distribution of Radioactivity in Dogs Dosed By Gavage
with 50 mg/kg of
[U-14C]Hydroquinone<a)





















^a^ Dogs were sacrificed at 168 hours.
(b) Values are expressed as an average for two dogs.
*c) Average, assuming 0.64
m2 for 12.3 kg dog. The surface area was
calculated using the formula: Area (sq. cm.) = 11.6 x weight 2/3.
30
Figure 5. Concentration of radioactivity in the blood following oral
administration of [U-14C]hydroquinone (50 mg/kg) to male Beagle
dogs. Blood samples (0.3 mL) were combusted directly using a Packard
Sample Oxidizer and counted in a scintillation fluid containing
Permaflour and Carbosorb. 14C disintegrations per minute
(dpm) was converted to nmol equivalents hydroquinone /mL blood.
Calculated half-life values (hr) : a = 0.85, P = 12.5. Data







































days, the concentration was 7.1 nmole equiv./mL. The elimination
profile was similar to that seen after the iv administration. After
an initial rapid distribution phase, the radioactivity declined
slowly. The half life values for the distribution and elimination
phases were estimated to be 0.85 and 12.5 hr, respectively.
The rate of percutaneous absorption and the elimination of
14
radioactivity following a 60 minute skin exposure to [ C]HQ
(4.5 g/L) are summarized in Table 5. The assumption is made that
14
the metabolic fate and disposition of [ C]HQ is similar after iv
14
or skin administration. After dermal application of [ C]HQ,
urinary excretion of radioactivity was low. The highest
concen-
14
trations of C were generally detected in the 24 to 48 hour
14
collections (Figure 6). The total amount of C excreted by 48
hours was equivalent to about 149 nmoles of HQ and by 120 hours was
about 171 nmole of HQ. The average percutaneous absorption rate,
calculated using the 48 hour excretion data for the dermal and iv
2 2
experiments, was approximately 0.16 nmoles/cm /minute (1.1/ug/cm hr) .
No measurable concentration of radioactivity (< 0.025 ug/mL) was





















































































































































































































































































































































Figure 6 . The cumulative urinary excretion of radioactivity by dogs
after dermal application of [U-14C]hydroquinone (4.5 g/L) for 60
minutes. Values represent the mean from 2 to 5 dogs with standard
error shown as vertical bars . Urine was treated with ascorbate and
was subsequently counted directly in scintillation fluid (1.0 mL) .
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HPLC Analysis
All dose solutions were analyzed by hplc. Radiochemical
detection was done to verify the radiochemical purity of the
14
[U- C]hydroquinone. Figure 7 (a-b) shows a representative
chromatogram from the analysis of a 1 mg/kg iv dose solution.
Ascorbic acid was added to inhibit oxidation. One uv and radio
active peak was seen. The retention time (9.75 min) was compared to
that of an authentic sample of hydroquinone, Figure 7 (c-d).
Unhydrolyzed urine (whole and extracted, collected 4 hours after
an iv dosing), contained at least 4 to 5 major and 2 to 3 small
radioactive components as detected by hplc analysis. Figure 8 (a-c)
shows representative chromatograms of whole unhydrolyzed urine from
the iv administration (1 mg/kg and 10 mg/kg) and oral dosing
(50 mg/kg) . The figures revealed that there is no significant amount
of free hydroquinone in the urine (retention time was compared to
that of an authentic sample of hydroquinone) .
Figure 9 shows a bar graph depicting 4 of the fractions
collected from extracts of unhydrolyzed 4-hour urine collections.
The first collection and largest component contained about 66.4% of
14
the total C injected and represented a collection time of 0 to
12 minutes. The second collection accounted for about 16.1% of the
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Figure 7 (a-b). U.V. (top) and radioactive (bottom) hplc chromato
grams of a 1 mg/kg dose of [14C]hydroquinone. A dose containing
approximately 3.3 uCi/mL was diluted 50x with degassed water. A
50 uL injection was made. Mobile phase: formic acid (0.09%)
/methanol. A single U.V. and radioactive peak was seen. The








Figure 7 (c-d). High performance liquid chromatogram of an
authentic sample of hydroquinone compound. Fifty milligrams of HQ
and 500 mg of ascorbic acid were diluted to 25 mL with degassed
water (boiled, then sonicated under reduced pressure), to give a
2 mg/mL stock solution. One hundred microliters of this stock
solution was diluted to 10 mL with degassed water to make a
20 ug/mL standard. [U-14C]Hydroquinone was added to make a
final solution of 270 ug/mL, containing approximately 0.47 uCi/mL.
Volume injected was 25 uL. Mobile phase: formic acid
(0.09%) /methanol. A single U.V. (top) and radioactive (bottom) peak






Figure 8 (a-c). U.V. (left) and radioactive (right) chromatograms
from hplc analysis of unhydrolyzed whole urine. Urine was collected
4 hours after the dog received either an iv administration (1 mg/kg
or 10 mg/kg). or an oral dose of [U-14C]hydroquinone. U.V.
absorption was monitored at 295 nm.
Volume of sample injected was 75, 100 and 25 uL for an iv dose of
1 and 10 mg/kg and an oral dose of 50 mg/kg, respectively. The















Figure 9. Bar graph of radioactive fractions collected from an hplc
analysis of extracts from unhydrolyzed urine (20 uL) . Urine was
collected 4 hours after dogs received an iv administration of 10 mg/kg
[U-14C]hydroquinone. The radioactivity, monitored at 295 nm, is
reported as ^C counts per minute (cpm) as determined by liquid
scintillation spectrometry.
Peaks 1, 2, 3, and 4 contained about 66.4%, 16.1%, 12.8% and 4.7% of



















_ ^ -i a a o
(spuDsnoqi) Wd3
45
injected C and was collected from 12 to 17 minutes. The third
peak collected from 17 to 20.4 minutes, contained 12.8% of the total
14
C. The fourth radioactive peak collected had 4.7% of the injected
14
C. The collection time was 20.4 to 30 minutes. An authentic
sample of hydroquinone had a retention time of 12.4 minutes.
Because of interfering substances in the concentrated fractions
collected from unhydrolyzed whole and extracted urine and the apparent
instability of the metabolites, identification of these peaks could
not be determined by gas chromatographic /mass spectroscopic analysis.
Treatment of urine with P-glucuronidase, aryl sulfatase or HC1
for identification of urinary conjugates, indicated that the urine of
iv and orally-treated dogs did not contain glucuronides of hydro
quinone. Preliminary evidence suggests the presence of a sulfuric
acid conjugate, but does not appear to be hydroquinone monosulfate.
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DISCUSSION
These studies accessed quantitatively the percutaneous absorption
of hydroquinone in a solution equivalent to that found in commercial
black and white photographic developer and investigated the metabolic
fate of hydroquinone after iv or oral administration in the dog.
Of interest in these studies was the relatively low recoveries of
14
C in the iv studies. Recoveries of 35% and 66% in the iv studies
(1 mg/kg and 10 mg/kg) and 80.4% of the dose with oral dosing were seen
in the urine. About 7.1, 6.1, and 4.0% of the dose was found in the
feces for iv dosing of 1 or 10 mg/kg and oral dosing, respectively.
suggesting that biliary excretion of hydroquinone and/or its metabolites
14
was occurring. The concentration of C in the blood declined slowly
after iv or oral dosing. This may suggest that there is a compartment
in the dog acting as a
"depot"
where the radioactivity is retained.
The elimination half-life values were 7.2, 8.0, and 12.5 hrs for the iv
1 mg/kg, 10 mg/kg, and the oral doses, respectively. The concentration
of radioactivity in the tissues other than skin was low. The liver
contained 0.3 to 0.6% of the dose after iv or oral administration. The
low concentration seen in the bone marrow was interesting, since Irons
et al. (1979) reported that in rats administered benzene, HQ was formed
in the bone marrow and the HQ persisted long after blood levels had
declined.
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An explanation of the relatively low recovery of radioactivity from
,14
,
[ CJHQ is unclear at this time. The assumption was made that the
skin samples tested were representative of the total skin area. The
possibility remains that the sample may not be representative, and that
the skin area may contain a considerable larger proportion of the
remaining radioactivity than estimated by this method.
Based on our findings of the lower dose iv studies, one can
speculate that the majority of the unaccounted radioactivity may reside
in the skin. These findings were unexpected and had not been reported
.previously.
Our findings indicate that the metabolism of hydroquinone in the
rat was different from the dog. Lockhart, et al. , (1984), found that
HQ administered orally to rats, was rapidly absorbed from the
gastrointestinal tract and was rapidly excreted in the urine. Within
8 hours, over 90% of the dose was excreted in the urine, in contrast to
only 20% of the dose seen in the dog after a 1 mg/kg iv administration
and 74% after an oral dose. Woodard (1951) also reported low urinary
recoveries in dogs dosed orally with 50 mg/kg HQ. The metabolites of
14
[ C]HQ in the urine of iv or orally dosed dogs were also different
from those in the urine of orally dosed rats (Figure 10) . Apparently
the route of metabolism is different for the 2 species. Reverse phase
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hplc analysis of radioactivity in the urine showed that the dog urine
contained more radioactive components than were found in rat urine.
Only 2 major components were seen in the rat urine. A small amount of
free hydroquinone was seen in the urine of both species. Garton and
Williams (1949a) reported similar findings in rabbits dosed with 100 to
400 mg/kg HQ.
After the treatment of the urine with hydrolytic enzymes,
preliminary evidence indicated that neither the sulfate nor the
glucuronide of HQ was present in any appreciable quantity in dog urine.
The metabolites in the dog urine may be conjugation products with
glutathione or with other amino acids. Hydroquinone has been shown to
be metabolized to benzoquinone in vitro and the benzoquinone has been
known to react rapidly with glutathione and cysteine (Lunte and
Kissinger, 1983). Enzyme treatment of rat urine (Figure 11) shows that
the 2 major components in the rat urine were HQ monosulfate and HQ
monoglucuronide with retention times of approximately 6.5 and 13.5
minutes, Figure 11 (a), respectively. On hydrolysis these moieties
gave rise to a peak at approximately 16.4 minutes, corresponding to HQ
Figure 11 (b,c). A small peak with retention time of 22 minutes was
present in all samples and the retention time of this peak was
unchanged by enzyme treatment. The sulfate hydrolysis was not
49
Figure 10 (a-c). Radioactive chromatograms from the hplc analysis of
unhydrolyzed whole dog and rat urine. Dog urine, Figure 10 (a-b), was
collected 4 hours after an iv administration (10 mg/kg) or an oral dose
(50 mg/kg) of [U-14C]hydroquinone. Rat urine, Figure 10 (c), was
collected 8 hours after an oral dose of 50 mg/kg [U-^c]hydroquinone.
Urine was filtered by passage through a 0.45 ym Millipore filter and
analyzed directly.
Volume of sample injected was 25, 100, and 50 uL for a dog, iv and
oral dose, and for a rat orally dosed, respectively.
U.V. absorption was monitored at 295 nm. Mobile phase: formic acid
(0.09%) /methanol. The hydroquinone peak was compared to that of an









complete by 4 hours Figure 11 (c). Lockhart et al. , (1984) reported
that hydroquinone glucuronide accounted for 61.3 to 63.9% of the dose,
after 8 hours and hydroquinone sulfate accounted for 19.1 to 26.2% of
the dose in the urine of rats dosed orally with 50 mg/kg [ C]HQ.
These findings are in agreement with those of DiVincenzo et al. ,
(1984) in which rats dosed orally with 200 mg/kg of [ C]HQ,
excreted 91.9% of the dose in the urine within 2-4 days, and the only
radiolabeled compounds in the urine were HQ monoglucuronide and HQ
monosulfate.
Percutaneous absorption studies indicated that the extent of
absorption of hydroquinone from a 60 minute dermal exposure was very
2
low. The absorption rate of 0.16 nmole/cm /min was much slower than
those of lipid soluble compounds such as aliphatic ketones and glycol
ethers, using the same animal model system. The absorption rates from
methyl n-butyl ketone (Di Vincenzo et al. , 1978), 2-propoxyethyl
acetate and 2-ethoxyethyl acetate (Guest et al. , 1985). were 240, 219,
2
and 179 nmole/cm /min, respectively. Further evidence that the
extent of absorption of hydroquinone is low is seen in published
in vitro studies with rat skin (Marty et al. , 1981). The percutaneous
absorption rate was similar to that seen in vivo in the dog. For human
skin, the rate of absorption was slower by a factor of 7 than that
seen in the rat.
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Figure 11 (a-c) . Radioactive chromatograms from the hplc analysis of
untreated (11-a) and hydrolyzed (ll-b,c) rat urine. Urine was collected
8 hours after the test animal received an oral dose of 50 mg/kg
[U- 4C]hydroquinone. Urine sample was prepared as follows:
Urine P-Rlucuronidase Sulfatase/Saccharolactone Buffer Code
0..5 mL 0 0 1..0 mL 11(a)
0..5 mL 1..0 mL 0 0 1Kb)
0..5 mL 0 1 .0 0 11(c)
A 10 mM saccharolactone solution was added to inhibit the P-glucuron
idase activity in the sulfatase preparation. The enzymes were prepared
in a 0.1M sodium acetate buffer, pH 5.5. The final incubation mixture
contained 1,800 and 5,000 Fishman units /mL of aryl sulfatase and P-
glucuronidase, respectively.
Samples were incubated at 37C for 4 hours, filtered through a 0.45 *m
centrifugal filter (using a Whatman #1 pre-filter) and analyzed
directly by hplc (100 uL) , using a 23 cm RP-18 MPLC column. U.V.
absorption was monitored at 295 nm.









The percutaneous absorption rate found in dogs may be used to
estimate the dermal uptake of hydroquinone by humans . Assuming a total
2
surface area of 1.85 m for an average adult (of which the hands
comprise 4% of the total) , immersion of both hands for 60 minutes in a
photographic developer solution containing HQ would result in the
absorption of about 0.8 mg of hydroquinone (i.e. 11.2 yg/kg for a
70 kg man) . These findings suggest that skin contact is unlikely to be
a significant route of HQ absorption by humans.
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C. Dermal Studies - Raw Data
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Dermal absorption of 14C-hydroquinone

































































Dermal absorption of 14C-hydroquinone




















































3 urine (8-24hr) ND ND
ND ND
4 urine (8-24hr) ND ND
ND ND
5 urine (8-24hr) ND ND
ND ND
6 urine (8-24hr) ND ND
ND ND



























Dermal absorption of 14C-hydroquinone
















1 urine (8-12hr) ND ND ND ND
2 urine (8-12hr) ND ND ND ND




































7 urine (8-12hr) ND ND ND ND
8 urine (8-12hr) ND ND ND ND





































ND ND ND ND





































ND ND ND ND
ND ND ND ND








Dermal absorption of 14C-hydroquinone
















1 urine (24-48hr) ND ND ND ND
2 urine (24-48hr) ND ND ND ND






































ND ND ND ND
8 urine (24-48hr)
ND ND ND ND


















































































Dermal absorption of 14C-hydroquinone















































































1 urine (96-120hr) ND ND ND ND
2 urine (96-120hr) ND ND ND ND
3 urine (96-l20hr) ND ND ND ND
4 urine (96-120hr) ND ND ND ND


















7 urine (96-120hr) ND ND ND ND
8 urine (96-120hr) ND ND ND ND

























1 urine (120-144hr) ND ND ND ND
2 urine (120-144hr) ND ND ND ND
3 urine (120-144hr) ND ND ND ND
4 urine (120-144hr) ND ND ND ND


















7 urine (120-144hr) ND ND ND ND
8 urine (120-144hr) ND ND ND ND








Dermal absorption of 14C-hydroquinone
















1 urine (144-168hr) ND ND ND ND
2 urine (144-168hr) ND ND ND ND
3 urine (144-168hr) ND ND ND ND
4 urine (144-168hr) ND ND ND ND


















7 urine (144-168hr) ND ND ND ND
8 urine (144-168hr) ND ND ND ND
ND - not determined
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ROUTE OF ADMINISTRATION: Intravenous
Dermal absorption of 14C-hydroquinone
[U-14C-Phenyl ] 1 , 4-dihydroxybenzene
1 mg/kg
SOURCE : LN-450,452,466 and File



































































EXPERIMENT NAME: Dermal absorption of 14C-hydroquinone
TEST COMPOUND: [U-14C-Phenyl] 1, 4-dihydroxybenzene
NOMINAL CONCENTRATION: 1 mg/kg
ROUTE OF ADMINISTRATION: Intravenous
SOURCE: LN-450,452,466 and File




































































EXPERIMENT NAME: Dermal absorption of 14C-hydroquinone
TEST COMPOUND: [U-14C-Phenyl] 1, 4 -dihydroxybenXnS
NOMINAL CONCENTRATION: 1 mg/kg
um a o ze e
ROUTE OF ADMINISTRATION: Intravenous
SOURCE: LN-450,452,466 and File
SAMPLING TYPE: Analyses of whole blood (combusted)
Sample
Dog # Description







































































EXPERIMENT NAME: Dermal absorption of 14C-hydroquinone
TEST COMPOUND: [U-14C-Phenyl] 1, 4-dihydroxybenzene
NOMINAL CONCENTRATION: 1 mg/kg
ROUTE OF ADMINISTRATION: Intravenous
SOURCE: LN-450,452,466 and File




































































ROUTE OF ADMINISTRATION: Intravenous
SOURCE:
LN-450,452,466 and File


































































* vial leakage-value not incorporated
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EXPERIMENT NAME: Dermal absorption of 14C-hydroquinone
TEST COMPOUND: [U-14C-Phenyl] 1, 4-dihydroxybenzene
NOMINAL CONCENTRATION: 1 mg/kg
ROUTE OF ADMINISTRATION: Intravenous
SOURCE: LN-450,452,466 and File



































































EXPERIMENT NAME: Dermal aV,=rvv-s4-^ ,, w* , v. ^




ROUTE OF ADMINISTRATION: Intravenous
S0URCE:
LN-450,452,466 and File








1 Blood (3 hours) 0.30
0.30
0.30
2 Blood (3 hours) 0.30
0.30
0.30
3 Blood (3 hours) 0.30
0.30
0.30
4 Blood (3 hours) 0.30
0.30
0.30
















Blood (3 hours) 0.30 472 1548
0.30 449
0.30 472
Blood (3 hours) 0.30 7325 27998
0.30 8829
0.30 9044




EXPERIMENT NAME: Dermal absorption of 14C-hydroquinone
TEST COMPOUND: [U-14C-Phenyl] 1, 4-dihydroxybenzene
NOMINAL CONCENTRATION: 1 mg/kg
ROUTE OF ADMINISTRATION: Intravenous
SOURCE: LN-450,452,466 and File



































































EXPERIMENT NAME: Dermal absorption of 14C-hydroquinone
TEST COMPOUND: [U-14C-Phenyl] 1, 4-dihydroxybenzene
NOMINAL CONCENTRATION: 1 mg/kg
ROUTE OF ADMINISTRATION: Intravenous
SOURCE: LN-450,452,466 and File



































































EXPERIMENT NAME: Dermal absorption of 14C-hydroquinone
TEST COMPOUND: [U-14C-Phenyl] 1, 4-dihydroxybenzene
NOMINAL CONCENTRATION: 1 mg/kg
ROUTE OF ADMINISTRATION: Intravenous
SOURCE: LN-450,452,466 and File


































































* value not incorporated - contamination suspected
39
EXPERIMENT NAME: Dermal absorption of 14C-hydroquinone
TEST COMPOUND: [U-14C-Phenyl] 1, 4-dihydroxybenzene
NOMINAL CONCENTRATION: 1 mg/kg
ROUTE OF ADMINISTRATION: Intravenous
SOURCE: LN-450,452,466 and File





































































4.842g of clotted blood digested to give 9.684g of solution
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EXPERIMENT NAME: Dermal absorption of 14C-hydroquinone
TEST COMPOUND : [U-14C-Phenyl ] 1 , 4-dihydroxybenzene
NOMINAL CONCENTRATION: 1 mg/kg
ROUTE OF ADMINISTRATION: Intravenous
SOURCE: LN-450,452,466 and File



































































EXPERIMENT NAME: Dermal absorption of 14C-hydroquinone
TEST COMPOUND: [U-14C-Phenyl] lf 4-dihydroxybenzene
NOMINAL CONCENTRATION: 1 mg/kg
ROUTE OF ADMINISTRATION: Intravenous
SOURCE: LN-450,452,466 and File
SAMPLING TYPE: Analyses of whole blood (combusted)
Sample Aliquot DPM per Mean
Dog # Description volume (mL) aliquot DPM/mL
1 Blood (12 hours) ND ND
Blood (12 hours) ND ND ND
Blood (12 hours) 0.30 165 574
Blood (12 hours) 0.30 330 1114











Blood (12 hours) 508
Blood (12 hours) 304
Blood (12 hours) ND ND ND
Blood (12 hours) ND ND ND
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EXPERIMENT NAME: Dermal absorption of 14C-hydroquinone
TEST COMPOUND: [U-14C-Phenyl] 1 , 4-dihydroxybenzene
NOMINAL CONCENTRATION: 1 mg/kg
ROUTE OF ADMINISTRATION: Intravenous
SOURCE: LN-450,452,466 and File
SAMPLING TYPE: Analyses of whole blood (combusted)
Sample Aliquot DPM per Mean
Dog # Description volume (mL) aliquot DPM/mL
I Blood (24 hours) ND ND
Blood (24 hours) ND ND ND
Blood (24 hours) 0.30 48 160
0.30 49
0.30 47
Blood (24 hours) 0.30 66 212
0.30 62
0.30 63
Blood (24 hours) 0.30 46 147
0.30 40
0.30 46















3.828g of clotted blood
digested to give 7.667g of solution
ND - not determined
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EXPERIMENT NAME: Dermal absorption of 14C-hydroquinone
TEST COMPOUND: [U-14C-Phenyl] 1 , 4-dihydroxybenzene
NOMINAL CONCENTRATION: 1 mg/kg
ROUTE OF ADMINISTRATION: Intravenous
SOURCE: LN-450,452,466 and File










1 Blood (48 hours) ND ND ND
Blood (48 hours) ND ND ND
Blood (48 hours) ND ND ND
Blood (48 hours) ND ND ND
Blood (48 hours) 0.30 20 60
0.30 16
0.30 18
Blood (48 hours) 0.30 21 62
0.30 17
0.30 18
Blood (48 hours) ND ND ND
Blood (48 hours) ND ND
ND
ND - not determined
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EXPERIMENT NAME: Dermal absorption of 14C-hydroquinone
TEST COMPOUND : [U-14C-Phenyl ] 1 , 4-dihydroxybenzene
NOMINAL CONCENTRATION: 1 mg/kg
ROUTE OF ADMINISTRATION: Intravenous
SOURCE: LN-450,452,466 and File
SAMPLING TYPE: Analyses of whole blood (combusted)
Sample Aliquot DPM per Mean
Dog # Description volume (mL) aliquot DPM/mL
I Blood (72 hours) ND ND
Blood (72 hours) ND ND ND
Blood (72 hours) ND ND ND
Blood (72 hours) ND ND ND
Blood (72 hours) 0.30 10 34
0.30 11
0.30 10
Blood (72 hours) 0.30 5 19
0.30 5
0.30 7
Blood (72 hours) ND ND ND
Blood (72 hours) ND ND ND
ND - not determined
45
Sa^oStkation: ^^"^^^-^hydroxybenzene
ROUTE OF ADMINISTRATION: Intravenous
SOURCE: LN-450,452,466 and File
SAMPLING TYPE: Analyses of whole blood (combusted)
Sample Aliquot DPM per Mean








1 Blood (96 hours) ND ND
2 Blood (96 hours) ND ND ND
3 Blood (96 hours) ND ND ND
4 Blood (96 hours) ND ND ND
5 Blood (96 hours) 21
6 Blood (96 hours)
7 Blood (96 hours) ND ND ND
8 Blood (96 hours) ND ND ND






































































































Spleen uCi 0.165 0.061 0.113
% of Dose 0.165 0.061 0.113
Stomach uCi 0.077 0.074 0.076
% of Dose 0.077 0.074 0.075
Testes uCi 0.020 0.011 0.015
% of Dose 0.020 0.010 0.015
*
surface area calculated using the following formula;
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Analyses of radioactive solutions
ASSAY: Dog #1 (# 447064)
Vol of dose DPM per uCi/mL
Sample counted (mL) aliquot dose
1 0 .002 *33606
2 h 35869 8.079
3 i 38734 8.724
4 ii 35824 8.068
5 n 38057 8.571
6 ii 39430 8.881
7 ii 36941 8.320
mean 37476 8.441
ASSAY : I3og #:2 (# 4568129) and Dog #3 (# 45<
Vol of dos DPM per uCi/mL
Sample counted (m aliquot dose


























SUMMARY 0]F: Urinary Radioactivity
Collection

















































































































Dermal absorption of 14C-hydroquinone






































































































2 urine (8-12hr) ND ND ND ND
3 urine (8-12hr) ND ND ND ND









2 urine (12-24hr) ND ND ND ND
3 urine (12-24hr) ND ND ND ND
1 urine (8-24hr) ND ND ND ND


























Dermal absorption of 14C-hydroquinone

















































Dermal absorption of 14C-hydroquinone









DPM per Mean total
aliquot DPM
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EXPERIMENT NAME: Dermal absorption of 14C-hydroquinone
TEST COMPOUND: [U-14C-Phenyl] 1, 4-dihydroxybenzene
NOMINAL CONCENTRATION: 10 mg/kg
ROUTE OF ADMINISTRATION: Intravenous
SOURCE: LN-450,452,466 and File
SAMPLING TYPE: Analyses of whole blood (combusted)
Sample Aliquot DPM per Mean
Dog # Description volume (mL) aliquot DPM/mL











































- not included in calculations
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EXPERIMENT NAME: Dermal absorption of 14C-hydroquinone
TEST COMPOUND: [U-14C-Phenyl ] 1 , 4-dihydroxybenzene
NOMINAL CONCENTRATION: 10 mg/kg
ROUTE OF ADMINISTRATION: Intravenous
SOURCE: LN-450,452,466 and File
SAMPLING TYPE: Analyses of whole blood (combusted)
Sample Aliquot DPM per Mean
Dog # Description volume (mL) aliquot DPM/mL











































EXPERIMENT NAME: Dermal absorption of 14C-hydroquinone
TEST COMPOUND: [U-14C-Phenyl] 1, 4-dihydroxybenzene
NOMINAL CONCENTRATION: 10 mg/kg
ROUTE OF ADMINISTRATION: Intravenous
SOURCE: LN-450,452,466 and File






















































EXPERIMENT NAME: Dermal absorption of 14C-hydroquinone
TEST COMPOUND: [U-14C-Phenyl] 1, 4-dihydroxybenzene
NOMINAL CONCENTRATION: 10 mg/kg
ROUTE OF ADMINISTRATION: Intravenous
SOURCE: LN-450,452,466 and File





















































EXPERIMENT NAME: Dermal absorption of 14C-hydroquinone
TEST COMPOUND: [U-14C-Phenyl] 1, 4-dihydroxybenzene
NOMINAL CONCENTRATION: 10 mg/kg
ROUTE OF ADMINISTRATION: Intravenous
SOURCE: LN-450,452,466 and File





















































EXPERIMENT NAME: Dermal absorption of 14C-hydrocruinone
TEST COMPOUND:
[U-14C-PhenylJ 1, 4-dihydroxybenzene
NOMINAL CONCENTRATION: 10 mg/kg
^
ROUTE OF ADMINISTRATION: Intravenous
SOURCE: LN-450,452,466 and File









Aliquot DPM per Mean




















EXPERIMENT NAME: Dermal absorption of 14C-hydroquinone
TEST COMPOUND: [U-14C-Phenyl] 1, 4-dihydroxybenzene
NOMINAL CONCENTRATION: 10 mg/kg
ROUTE OF ADMINISTRATION: Intravenous
SOURCE: LN-450,452,466 and File
SAMPLING TYPE: Analyses of whole blood (combusted)
Sample Aliquot DPM per Mean
Dog # Description volume (mL) aliquot DPM/mL







2 Blood (12 hours) ND ND ND
3 Blood (12 hours) ND ND ND
Blood (24 hours) 0.30 196 619
0.30 182
0.30 179
3 Blood (24 hours) 0.30 266 878
0.30 259
0.30 265
T* Blood (24 hours) 0.330 134 397
0.324 134
0.324 120
"I Blood (48 hours) 0.30 77 257
0.30 64
0.30 90
2 Blood (48 hours) 0.30 87 286
0.30 84
0.30 86
3 Blood (48 hours) 0.30 95 303
0.30 93
0.30 85
ND - not determined
* 5.924g of clotted blood
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I urine (0-4 hr)
2 urine (0-4 hr)
3 urine (0-4 hr)
4 urine (0-4 hr)
5 urine (0-4 hr)
6 urine (0-4 hr)
Dermal absorption of 14C-hydroquinone





Analyses of radioactive solutions
Sample Aliquot DPM per Mean total






























































Dermal absorption of 14C-hydroquinone

















































































Dermal absorption of 14C-hydroquinone





Analyses of radioactive solutions
Sample Aliquot DPM per Mean total
size(mL) size(mL) aliquot DPM
































































I urine (24-48 hr)
2 urine (24-48 hr)
3 urine (24-48 hr)
4 urine (24-48 hr)
5 urine (24-48 hr)
6 urine (24-48 hr)
Dermal absorption of 14C-hydroquinone





Analyses of radioactive solutions
Sample Aliquot DPM per Mean total
size(mL) size(mL) aliquot DPM
































Dermal absorption of 14C-hydroquinone
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EXPERIMENT: Dermal absorption of 14C-hydroquinone
TEST COMPOUND: [U-14C-Phenyl] 1, 4-dihydroxybenzene
NOMINAL CONCENTRATION: 4.5 g/L
ROUTE OF ADMINISTRATION: Dermal
SOURCE: LN-450,452,466 and File




































































































































































































































Dermal absorption of 14C-hydroquinone











































































Dermal absorption of 14C-hydroquinone











































































Dermal absorption of 14C-hydroquinone
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EXPERIMENT: Dermal absorption of 14C-hydroquinone
TEST COMPOUND : [U-14C-Phenyl ] 1 , 4-dihydroxybenzene
NOMINAL CONCENTRATION: 50 mg/kg
ROUTE OF ADMINISTRATION: Oral gavage
SOURCE: LN-450,452,466 and File
SAMPLING TYPE: Urinary radioactivity
Sample Sample Aliquot
Dog # description size (mL) vol. (mL)
Urine (0-4 hr) 55.0
















































Dog # description size (mL) vol. (mL)
DPM per Mean total
aliquot DPM









































Dermal absorption of 14C-hydroquinone














Urine (144-168 hr) 415.0 1.00
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Dermal absorption of 14C-hydroquinone




SUMMARY OF: Blood radioactivity
Collection
























































































































SUMMARY OF: Blood radioactivity
Collection










































































































































































Dermal absorption of 14C-hydroguinone























































* vial leakage - not included in calculations
119
EXPERIMENT: Dermal absorption of 14C-hydrocruinone
TEST COMPOUND: [U-14C-Phenyl] 1,4-dihydroxybSnSie
NOMINAL CONCENTRATION: 50 mg/kg
i-u cenzen
ROUTE OF ADMINISTRATION: Oral gavage
SOURCE: LN-450,452,466 and File
SAMPLING TYPE: Whole blood (combusted)
Sample Aliquot DPM per
1 Blood (24 hours) 0.30 183
196
177
2 Blood (24 hours) 0.30 334
319
342
Blood (48 hours) 0.30 114
116
114





Blood (48 hours) 0.30 234 762
224
228
1 Blood (72 hours) 0.30 94 297
84
89
2 Blood (72 hours) 0.30 190 644
191
199
T Blood (96 hours) 0.30 72 247
70
76




EXPERIMENT: Dermal absorption of 14C-hydroquinone
TEST COMPOUND: [U-14C-Phenyl] 1, 4-dihydroxybenzene
NOMINAL CONCENTRATION: 50 mg/kg
ROUTE OF ADMINISTRATION: Oral gavage
SOURCE: LN-450,452,466 and File
SAMPLING TYPE: Whole blood (combusted)
* vial not counted
Sample Aliquot DPM per Mean
Dog # description volume (mL) aliquot DPM per mL
I Blood (120 hours) 6T30 67
61
70
2 Blood (120 hours) 0.30 140 517
170
*
I Blood (144 hours) 6T30 58 198
60
61
2 Blood (144 hours) 0.30 141 454
136
132






























































































































** skin surface area
calculated usin g the following
formula,
area (sq.cm)
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Intravenous and Oral Administration
A: X 14C in blood = (uCi/mL x weight of dog (kg) x 94.1 mL/kg(a)
uCi of dose
B: % 14C in skin - (liCi/g skin) x g/cm2 skin(b) x surface area (cm2)(a)
pCi of dose
Surface area K x (weighting)2/3, K - 11.6 for dog(a)
Dermal Application
A: percutaneous absorption rate * nmoles absorbed
(nmole/cm2/minute) (surface area exposed x exposure time)
nmoles excreted in urine/% in urine after iv dose^c^
55.6 cm2 x 60 minutes
(a)See reference 1; (^'determined empirically for each dog
(c'At same time period
132
